HK Stock Market Move | INSILICO (03696) surged over 10% as it partners with Yuanma Zhiyao to develop the next generation of mRNA tumor vaccines.

INSILICO (03696) rose over 10%, currently up 10.25%, priced at HK$44.54, with a trading volume of HK$538 million. On the news front, the recent Phase III clinical trial of the AI+mRNA personalized cancer vaccine jointly developed by Moderna and Merck was a complete success, sparking interest in mRNA and AI-driven pharmaceuticals. INSILICO, as a leading enterprise in the field of AI pharmaceutical development, possesses strong model validation and delivery capabilities in the AI4S pharmaceutical space. On August 20, INSILICO also announced a research collaboration with the next-generation RNA innovative medicine company, Yuanma Zhiy. The two parties will collaborate in areas such as AI new antigen prediction and sequence design, circular mRNA, targeted delivery, automated experiments, and smart manufacturing to co-build a next-generation mRNA AI native research and development system. A recent research report from Guotai Haitong pointed out that multiple molecular outputs from the company's Pharma.AI platform have already achieved a series of licensing agreements with domestic and international pharmaceutical companies, and MMAIGym is expected to drive the companys transition from AI drug discovery project-based collaborations to a platform monetization model that includes "model training infrastructure + data/model licensing + cloud invocation." Based on comparable companies, it assigns the company a P/S ratio of 29 for 2026, with a target price of HK$73.23, and recommends an "overweight" rating.